Sartorius and Mabion Announce Strategic Cooperation to Advance Biopharmaceutical Development
Sartorius is expanding its CDMO network and has entered into a CDMO collaboration with Mabion S.A., a biopharmaceutical company based in Poland, to offer customers comprehensive services that streamline timelines, reduce complexity, and deliver high-quality biologics to market faster and more efficiently.
Under this non-exclusive agreement, Sartorius and Mabion will offer an integrated range of services. Sartorius will focus on lab-scale development by leveraging its proprietary cell culture media along with expertise in cell line development and upstream process optimization. Mabion will focus on further development of upstream processes, including confirmation in 10L-scale bioreactors, downstream process optimization, and analytics, along with validation, scale-up with process characterization, and large-scale manufacturing services.
“This cooperation represents a significant milestone for Mabion. Partnering with Sartorius enables us to further expand our CDMO service portfolio and address the growing demand for comprehensive solutions in the biopharmaceutical industry. We are excited about the opportunities this partnership will unlock for our customers and their patients worldwide.” Krzysztof Kaczmarczyk, CEO of Mabion.
“Our partnership with Mabion underscores our commitment to advancing biopharmaceutical development through collaboration. By combining our cutting-edge cell line development technologies with the proven manufacturing capabilities demonstrated by Mabion, we deliver an end-to-end solution that benefits our customers and drives innovation in the field.” Heike Mayer, Head of Operations Ulm, Lab Operations ATS at Sartorius.
Key aims of the collaboration:
- Creating an end-to-end solution: Customers can access integrated services that offer lab-scale process development expertise from Sartorius with scale-up and manufacturing capabilities from Mabion.
- Maintaining quality and innovation: The collaboration combines both companies’ demonstrated expertise in GMP manufacturing and experience enabling customers to deliver high-quality biologics.
- Enhancing customer synergies: By offering a comprehensive solution, the collaboration will help raise customer awareness as well as meet their specific needs.
- Proprietary cell culture media: As part of the agreement, Sartorius will supply its proprietary cell culture media, trusted by manufacturers, to ensure compatibility and optimize results.
Through this collaboration, the companies will provide customers with a one-stop solution from DNA to manufacturing, that reduces the logistics and administrative efforts associated with managing multiple stakeholders. Leveraging services from Sartorius and Mabion will reduce customers’ time to clinic and help bring their therapeutic molecule to market faster.
About Mabion S.A.: Mabion S.A. (WSE: MAB) is a Polish biopharmaceutical company founded in 2007, which is undergoing a transformation into a fully integrated contract development and manufacturing organization (CDMO) providing a broad spectrum of services in the segment of small and medium-sized projects at various stages of development (from process development stage to commercial manufacturing). Mabion’s competencies include protein production using mammalian cell cultures, protein purification, GMP-standard manufacturing activities (obtaining Active Substances “Drug Substance” and Finished Products “Drug Product”), development of analytical tools (for structural, functional, physicochemical characterization) and clinical development. The company signed a record contract with Novavax in October 2021 for the commercial production of antigen for the COVID-19 vaccine, which it has since steadily expanded through further services under statements of work concluded and annexes signed, adding, among other things, another vaccine product based on the Omicron variant. According to the strategy, announced in April 2023, the company’s goal is to establish itself as a recognizable player in the global contract manufacturing and contract drug development market and to complete Mabion’s full transformation into an integrated biologics CDMO company. Mabion is a public company, listed on the Warsaw Exchange.
About Sartorius: Sartorius is a leading international partner of life sciences research and the biopharmaceutical industry. With innovative laboratory instruments and consumables, the Group’s Lab Products & Services division focuses on laboratories performing research and quality control at pharmaceutical and biopharmaceutical companies as well as academic research institutes. The Bioprocess Solutions division, with its broad product portfolio focusing on single-use solutions, helps customers manufacture biotech medications, vaccines, and cell and gene therapies safely, rapidly, and economically. The company, based in Göttingen, Germany, has a strong global reach with around 60 production and sales sites worldwide. Sartorius regularly expands its portfolio through acquisitions of complementary technologies. In 2024, the company generated sales revenue of around 2.8 billion euros, according to preliminary figures. Currently, more than 13 500 employees are working for customers around the globe.
Follow Sartorius on LinkedIn and Facebook.
Contact Mabion
For media inquiries:
Michał Wierzchowski
+48 531 613 067
+48 22 440 14 40
michal.wierzchowski@ccgroup.pl
For institutional investors and analysts:
Piotr Owdziej
+48 697 612 913
+48 22 440 14 40
piotr.owdziej@ccgroup.pl
Contact Sartorius
Leona Malorny
Head of External Communications
+49 551 308 4067
leona.malorny@sartorius.com
Heike Mayer
Head of Operations Ulm
+49 731 206 52181
heike.mayer@sartorius.com